Role of bioinformatics and pharmacogenomics in drug discovery and development process

Network Modeling and Analysis in Health Informatics and Bioinformatics

Volumn 2, Issue 4, 2013, Pages 225-230

  Katara, Pramod ^a,b  

^a BANASTHALI UNIVERSITY   (India)

^b UNIVERSITY OF ALLAHABAD   (India)

Author keywords

Bioinformatics; Drug; New chemical entity; Pharmacogenomics; Variable drug response

Indexed keywords

BIOINFORMATICS; COMMERCE; COST REDUCTION; INVESTMENTS;

DEVELOPMENT PROCESS; DRUG; DRUG RESPONSE; MANUFACTURING STANDARD; NEW CHEMICAL ENTITIES; PHARMACEUTICAL COMPANY; PHARMACOGENOMICS; RESEARCH AND DEVELOPMENT;

DRUG PRODUCTS;

ARTICLE; BIOINFORMATICS; COMPUTER AIDED DESIGN; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG MARKETING; DRUG SCREENING; DRUG TARGETING; ECONOMIC ASPECT; GENETIC POLYMORPHISM; HOSPITALIZATION; HUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; VALIDATION PROCESS;

EID: 84900450967     PISSN: None     EISSN: 21926670     Source Type: Journal    
DOI: 10.1007/s13721-013-0039-5     Document Type: Article

References (56)

1. Adams CP, Brantner VV (2010) Spending on new drug development. Health Econ 19: 130-141.
2. Amstutz U, Carleton BC (2011) Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther 89: 924-927.
3. Becquemont L (2009) Pharmacogenomics of adverse drug reactions: practical applications and perspectives. Pharmacogenomics 10: 961-969.
4. Becquemont L, Alfirevic A, Amstutz U, Brauch H, Jacqz-Aigrain E, Laurent-Puig P, Molina MA, Niemi M, Schwab M, Somogyi AA, Thervet E, Maitland-van der Zee AH, van Kuilenburg AB, van Schaik RH, Verstuyft C, Wadelius M, Daly AK (2011) Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics 12: 113-124.
5. Bernard S (2003) The 5 Myths of Pharmacogenomics. Pharm Executive 23: 70-78.
6. Blundell TL, Sibanda BL, Montalvao RW, Brewerton S, Chelliah V, Worth CL, Harmer NJ, Davies O, Burke D (2006) Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos Trans R Soc Lond B Biol Sci 361: 413-423.
7. Chen YP, Chen F (2008) Identifying targets for drug discovery using bioinformatics. Expert Opin Ther Targ 12: 383-389.
8. Collier R (2009) Rapidly rising clinical trial costs worry researchers. CMAJ 180: 277-278.
9. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE (2012) Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther 92: 467-475.
10. Dhaliwal B, Chen YW (2009) Computational resources for protein modelling and drug discovery applications. Infect Disord Drug Targ 9: 557-562.
11. Dickson M, Gagnon JP (2004a) Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov 3: 417-429.
12. Dickson M, Gagnon JP (2004b) The cost of new drug discovery and development. Discov Med 4: 172-179.
13. Du QS, Huang RB (2012) Recent progress in computational approaches to studying the M2 proton channel and its implication to drug design against influenza viruses. Curr Protein Pept Sci 13: 205-210.
14. Gilbert J, Henske P, Singh A (2003) Rebuilding Big Pharma's Business Model. In vivo Business and Medicine Report 21, p 10.
15. Ginsburg GS, Willard HF (2009) Genomic and personalized medicine: foundations and applications. Transl Res 154: 277-287.
16. Gomase VS, Tagore S, Changbhale SS, Kale KV (2008) Pharmacogenomics. Curr Drug Metab 9: 207-212.
17. Haga SB, Burke W (2011) Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests. Clin Pharmacol Ther 90: 25-27.
18. Hecker N, Ahmed J, von Eichborn J, Dunkel M, Macha K, Eckert A, Gilson MK, Bourne PE, Preissner R (2012) Super target goes quantitative: update on drug-target interactions. Nucleic Acids Res 40: D1113-D1117.
19. Iskar M, Zeller G, Zhao XM, van Noort V, Bork P (2012) Drug discovery in the age of systems biology: the rise of computational approaches for data integration. Curr Opin Biotechnol 23: 609-616.
20. Katara P, Grover A, Kuntal H, Sharma V (2011) In silico prediction of drug targets in vibrio cholerae. Protoplasma 248: 799-804.
21. Klein DB, Tabarrok A (2003) The drug discovery, development and approval process. www. fdareview. org.
22. Kuhn M, Szklarczyk D, Franceschini A, Campillos M, von Mering C, Jensen LJ, Beyer A, Bork P (2010) STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res 38: D552-D556.
23. Laing RE, Hess P, Shen Y, Wang J, Hu SX (2011) The role and impact of SNPs in pharmacogenomics and personalized medicine. Curr Drug Metab 12: 460-486.
24. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients. JAMA 279: 1200-1205.
25. Liang BA, Mackey T (2011) Direct-to-consumer advertising with interactive internet media: global regulation and public health issues. JAMA 305: 824-825.
26. Lindpaintner K (2002) The impact of pharmacogenetics and pharmacogenomics on drug discovery. Nat Rev Drug Discov 1: 463-469.
27. Liou SY, Stringer F, Hirayama M (2012) The impact of pharmacogenomics research on drug development. Drug Metab Pharmacokinet 27: 2-8.
28. Loh M, Soong R (2011) Challenges and pitfalls in the introduction of pharmacogenetics for cancer. Ann Acad Med Singap 40: 369-374.
29. Maher PD, Haffner M (2006) Orphan drug designation and pharmacogenomics: options and opportunities. BioDrugs 20: 71-79.
30. Meyers S, Baker A (2001) Drug discovery: an operating model for a new era. Nat Biotechnol 19: 727-730.
31. Mullin R (2003) Drug Development Costs About $1. 7 Billion. Chemical and Engineering News April 2003.
32. Nelson MR, Bacanu SA, Mosteller M, Li L, Bowman CE, Roses AD, Lai EH, Ehm MG (2009) Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J 9: 23-33.
33. Ortega SS, Cara LC, Salvador MK (2012) In silico pharmacology for a multidisciplinary drug discovery process. Drug Metabol Drug Interact 27: 199-207.
34. Papanikolaw J (1999) Bioinformatics emerges as key technology for developing new drugs. Chem Mark Report 21: 22.
35. Prows CA, Prows DR (2004) Medication selection by genotype: how genetics is changing drug prescription and efficacy. Am J Nurs 104: 60-70.
36. Ratti E, Trist D (2001) Continuing evolution of the drug discovery process. Pure Appl Chem 73: 67-75.
37. Rawlins MD (2004) Cutting the cost of drug development? Nat Rev Drug Discov 3: 360-364.
38. Rioux PP (2000) Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health Syst Pharm 57: 887-901.
39. Scherf U, Becker R, Chan M, Hojvat S (2010) Approval of novel biomarkers: fDA's perspective and major requests. Scand J Clin Lab Invest Suppl 242: 96-102.
40. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K (2001) dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29: 308-311.
41. Shin J (2012) Clinical pharmacogenomics of warfarin and clopidogrel. J Pharm Pract 25: 428-438.
42. Sim SC, Ingelman-Sundberg M (2010) The human cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics 4: 278-281.
43. Simoens S (2011) Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 6: 42.
44. Song CM, Lim SJ, Tong JC (2009) Recent advances in computer-aided drug design. Brief Bioinform 10: 579-591.
45. Speck-Planche A, Cordeiro MN (2013) Computer-aided drug design, synthesis and evaluation of new anti-cancer drugs. Curr Top Med Chem [Epub ahead of print].
46. Tamimi NA, Ellis P (2009) Drug development: from concept to marketing! Nephron Clin Pract 113: c125-c131.
47. Thorisson GA, Smith AV, Krishnan L, Stein LD (2005) The international HapMap project web site. Genome Res 15: 1592-1593.
48. Thorn CF, Klein TE, Altman RB (2010) Pharmacogenomics and bioinformatics: pharmGKB. Pharmacogenomics 11: 501-505.
49. Tsaioun K, Bottlaender M, Mabondzo A, Alzheimer's Drug Discovery Foundation (2009) ADDME-avoiding drug development mistakes early: central nervous system drug discovery perspective. BMC Neurol 12: 9.
50. Vanakker OM, De Paepe A (2013) Pharmacogenomics in children: advantages and challenges of next generation sequencing applications. Int J Pediatr 2013: 136524.
51. Whittaker P (2003) What is the relevance of bioinformatics to pharmacology? Trend Pharmacol Sci 24: 434-439.
52. Wierenga DE, Eaton RC (2004) Drug Development and Approval Process. Alliance Pharmaceutical Company. http://www. allp. com/drug_dev. htm.
53. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B, Hassanali M (2008) DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res 36: D901-D906.
54. Yamanishi Y, Kotera M, Kanehisa M, Goto S (2010) Drug-target interaction prediction from chemical, genomic and pharmacological data in an integrated framework. Bioinformatics 26: i246-i254.
55. Zemlo T (2004) Pharmacogenomic promise, pitfalls. Drug discovery and development. Highland Ranch 7: 13.
56. Zhu F, Shi Z, Qin C, Tao L, Liu X, Xu F, Zhang L, Song Y, Liu X, Zhang J, Han B, Zhang P, Chen Y (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. Nucleic Acids Res 40: D1128-D1136.